Laurie Pearson to Aged
This is a "connection" page, showing publications Laurie Pearson has written about Aged.
Connection Strength
0.170
-
Pearson LK, Zheng Y, Nikita N, Lu-Yao G, Presley CJ, Wagner LI, Simon MA, Dotan E. Unveiling Factors Associated With Older Adult Accrual to Cancer Clinical Trials: Lessons From the ECOG-ACRIN Experience. J Natl Compr Canc Netw. 2025 Dec; 23(12).
Score: 0.075
-
Bhatia I, Patel SA, Pearson L, Parthiban K, Suzuki S, Bindal P, Gillis-Smith A, Ramanathan M, Gerber J, Nath R, Cerny J. Outcomes of adults older than 70 years of age undergoing allogeneic stem cell transplantation. Leuk Res. 2026 Jan; 160:108145.
Score: 0.019
-
Gauthier J, Ahn KW, Patel J, Lian Q, Badawy S, Cairo MS, Delgado J, Grover N, Haverkos B, de Lima M, Malone A, Mussetti A, Nieto Y, Pawarode A, Pearson L, Solh M, Sureda A, Tun AM, Wudhikarn K, Yamshon S, Shadman M, Turtle CJ, Hamadani M, Herrera AF. CD19 CAR T-Cell Therapy for Primary Mediastinal Large B-Cell Lymphoma: A CIBMTR Analysis. Am J Hematol. 2025 10; 100(10):1792-1802.
Score: 0.018
-
Khouri MR, Wang B, Pearson LK, Gillis-Smith AJ, Suzuki S, Hutchinson LM, Bindal P, Ramanathan M, Gerber JM, Cerny J, Patel SA. Characteristics and clinical outcomes of patients with myeloid malignancies and cohesin mutations. Cancer. 2025 Apr 15; 131(8):e35846.
Score: 0.018
-
Ter-Minassian M, Chan JA, Hooshmand SM, Brais LK, Daskalova A, Heafield R, Buchanan L, Qian ZR, Fuchs CS, Lin X, Christiani DC, Kulke MH. Clinical presentation, recurrence, and survival in patients with neuroendocrine tumors: results from a prospective institutional database. Endocr Relat Cancer. 2013 Apr; 20(2):187-96.
Score: 0.016
-
Eyre TA, Roeker LE, Fox CP, Gohill SH, Walewska R, Walter HS, Forconi F, Broom A, Arumainathan A, Brander DM, Allan JN, Schuster SJ, Hill BT, Lansigan F, Cheson BD, Lamanna N, Coombs CC, Barr PM, Skarbnik AP, Shadman M, Ujjani CS, Pearson L, Pagel JM, Jacobs R, Mato AR. The efficacy and safety of venetoclax therapy in elderly patients with relapsed, refractory chronic lymphocytic leukaemia. Br J Haematol. 2020 03; 188(6):918-923.
Score: 0.012
-
Roeker LE, Fox CP, Eyre TA, Brander DM, Allan JN, Schuster SJ, Nabhan C, Hill BT, Shah NN, Lansigan F, Yazdy M, Cheson BD, Lamanna N, Singavi AK, Coombs CC, Barr PM, Skarbnik AP, Shadman M, Ujjani CS, Tuncer HH, Winter AM, Rhodes J, Dorsey C, Morse H, Kabel C, Pagel JM, Williams AM, Jacobs R, Goy A, Muralikrishnan S, Pearson L, Sitlinger A, Bailey N, Schuh A, Kirkwood AA, Mato AR. Tumor Lysis, Adverse Events, and Dose Adjustments in 297 Venetoclax-Treated CLL Patients in Routine Clinical Practice. Clin Cancer Res. 2019 07 15; 25(14):4264-4270.
Score: 0.012